Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Clifford

Showing results (301-310 of 325) with videos related to

Pageof 33
Sort By:
Journal of Neurovirology|July 11, 2013
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infectionChristine Fennema-Notestine, Ronald J Ellis, Sarah L Archibald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2014
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER studyRobert K Heaton, Donald R Franklin, Reena Deutsch, et al.
The Lancet. Neurology|July 23, 2011
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringLudwig Kappos, David Bates, Gilles Edan, et al.
Neurology|December 8, 2010
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER StudyR K Heaton, D B Clifford, D R Franklin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumNelly Joseph-Mathurin, Charles D Chen, Diana A Hobbs, et al.
Neurology Open Access|July 8, 2025
A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH TrialKa-Ho Wong, Gregory Scott Day, James C Torner, et al.
Journal of Neurovirology|December 22, 2010
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsRobert K Heaton, Donald R Franklin, Ronald J Ellis, et al.
Frontiers in Aging Neuroscience|July 5, 2022
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention TrialsAndrew J Aschenbrenner, Jason Hassenstab, Guoqiao Wang, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Neurology. Clinical Practice|January 20, 2025
Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United StatesGiovanna Sophia Manzano, James Eaton, Michael Levy, et al.
Pageof 33

Showing results (301-310 of 325) with videos related to

Sort By:
Pageof 33
Journal of Neurovirology|July 11, 2013
Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infectionChristine Fennema-Notestine, Ronald J Ellis, Sarah L Archibald, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2014
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER studyRobert K Heaton, Donald R Franklin, Reena Deutsch, et al.
The Lancet. Neurology|July 23, 2011
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringLudwig Kappos, David Bates, Gilles Edan, et al.
Neurology|December 8, 2010
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER StudyR K Heaton, D B Clifford, D R Franklin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumNelly Joseph-Mathurin, Charles D Chen, Diana A Hobbs, et al.
Neurology Open Access|July 8, 2025
A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH TrialKa-Ho Wong, Gregory Scott Day, James C Torner, et al.
Journal of Neurovirology|December 22, 2010
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictorsRobert K Heaton, Donald R Franklin, Ronald J Ellis, et al.
Frontiers in Aging Neuroscience|July 5, 2022
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention TrialsAndrew J Aschenbrenner, Jason Hassenstab, Guoqiao Wang, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
Neurology. Clinical Practice|January 20, 2025
Consensus Recommendations for the Management of Neurosarcoidosis: A Delphi Survey of Experts Across the United StatesGiovanna Sophia Manzano, James Eaton, Michael Levy, et al.
Pageof 33